Cargando…

VLCKD: a real time safety study in obesity

BACKGROUND: Very Low-Calorie Ketogenic Diet (VLCKD) is currently a promising approach for the treatment of obesity. However, little is known about the side effects since most of the studies reporting them were carried out in normal weight subjects following Ketogenic Diet for other purposes than obe...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrea, Luigi, Verde, Ludovica, Vetrani, Claudia, Marino, Francesca, Aprano, Sara, Savastano, Silvia, Colao, Annamaria, Muscogiuri, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742928/
https://www.ncbi.nlm.nih.gov/pubmed/34998415
http://dx.doi.org/10.1186/s12967-021-03221-6
_version_ 1784629805010911232
author Barrea, Luigi
Verde, Ludovica
Vetrani, Claudia
Marino, Francesca
Aprano, Sara
Savastano, Silvia
Colao, Annamaria
Muscogiuri, Giovanna
author_facet Barrea, Luigi
Verde, Ludovica
Vetrani, Claudia
Marino, Francesca
Aprano, Sara
Savastano, Silvia
Colao, Annamaria
Muscogiuri, Giovanna
author_sort Barrea, Luigi
collection PubMed
description BACKGROUND: Very Low-Calorie Ketogenic Diet (VLCKD) is currently a promising approach for the treatment of obesity. However, little is known about the side effects since most of the studies reporting them were carried out in normal weight subjects following Ketogenic Diet for other purposes than obesity. Thus, the aims of the study were: (1) to investigate the safety of VLCKD in subjects with obesity; (2) if VLCKD-related side effects could have an impact on its efficacy. METHODS: In this prospective study we consecutively enrolled 106 subjects with obesity (12 males and 94 females, BMI 34.98 ± 5.43 kg/m(2)) that underwent to VLCKD. In all subjects we recorded side effects at the end of ketogenic phase and assessed anthropometric parameters at the baseline and at the end of ketogenic phase. In a subgroup of 25 subjects, we also assessed biochemical parameters. RESULTS: No serious side effects occurred in our population and those that did occur were clinically mild and did not lead to discontinuation of the dietary protocol as they could be easily managed by healthcare professionals or often resolved spontaneously. Nine (8.5%) subjects stopped VLCKD before the end of the protocol for the following reasons: 2 (1.9%) due to palatability and 7 (6.1%) due to excessive costs. Finally, there were no differences in terms of weight loss percentage (13.5 ± 10.9% vs 18.2 ± 8.9%; p = 0.318) in subjects that developed side effects and subjects that did not developed side effects. CONCLUSION: Our study demonstrated that VLCKD is a promising, safe and effective therapeutic tool for people with obesity. Despite common misgivings, side effects are mild, transient and can be prevented and managed by adhering to the appropriate indications and contraindications for VLCKD, following well-organized and standardized protocols and performing adequate clinical and laboratory monitoring.
format Online
Article
Text
id pubmed-8742928
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87429282022-01-10 VLCKD: a real time safety study in obesity Barrea, Luigi Verde, Ludovica Vetrani, Claudia Marino, Francesca Aprano, Sara Savastano, Silvia Colao, Annamaria Muscogiuri, Giovanna J Transl Med Research BACKGROUND: Very Low-Calorie Ketogenic Diet (VLCKD) is currently a promising approach for the treatment of obesity. However, little is known about the side effects since most of the studies reporting them were carried out in normal weight subjects following Ketogenic Diet for other purposes than obesity. Thus, the aims of the study were: (1) to investigate the safety of VLCKD in subjects with obesity; (2) if VLCKD-related side effects could have an impact on its efficacy. METHODS: In this prospective study we consecutively enrolled 106 subjects with obesity (12 males and 94 females, BMI 34.98 ± 5.43 kg/m(2)) that underwent to VLCKD. In all subjects we recorded side effects at the end of ketogenic phase and assessed anthropometric parameters at the baseline and at the end of ketogenic phase. In a subgroup of 25 subjects, we also assessed biochemical parameters. RESULTS: No serious side effects occurred in our population and those that did occur were clinically mild and did not lead to discontinuation of the dietary protocol as they could be easily managed by healthcare professionals or often resolved spontaneously. Nine (8.5%) subjects stopped VLCKD before the end of the protocol for the following reasons: 2 (1.9%) due to palatability and 7 (6.1%) due to excessive costs. Finally, there were no differences in terms of weight loss percentage (13.5 ± 10.9% vs 18.2 ± 8.9%; p = 0.318) in subjects that developed side effects and subjects that did not developed side effects. CONCLUSION: Our study demonstrated that VLCKD is a promising, safe and effective therapeutic tool for people with obesity. Despite common misgivings, side effects are mild, transient and can be prevented and managed by adhering to the appropriate indications and contraindications for VLCKD, following well-organized and standardized protocols and performing adequate clinical and laboratory monitoring. BioMed Central 2022-01-08 /pmc/articles/PMC8742928/ /pubmed/34998415 http://dx.doi.org/10.1186/s12967-021-03221-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Barrea, Luigi
Verde, Ludovica
Vetrani, Claudia
Marino, Francesca
Aprano, Sara
Savastano, Silvia
Colao, Annamaria
Muscogiuri, Giovanna
VLCKD: a real time safety study in obesity
title VLCKD: a real time safety study in obesity
title_full VLCKD: a real time safety study in obesity
title_fullStr VLCKD: a real time safety study in obesity
title_full_unstemmed VLCKD: a real time safety study in obesity
title_short VLCKD: a real time safety study in obesity
title_sort vlckd: a real time safety study in obesity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742928/
https://www.ncbi.nlm.nih.gov/pubmed/34998415
http://dx.doi.org/10.1186/s12967-021-03221-6
work_keys_str_mv AT barrealuigi vlckdarealtimesafetystudyinobesity
AT verdeludovica vlckdarealtimesafetystudyinobesity
AT vetraniclaudia vlckdarealtimesafetystudyinobesity
AT marinofrancesca vlckdarealtimesafetystudyinobesity
AT apranosara vlckdarealtimesafetystudyinobesity
AT savastanosilvia vlckdarealtimesafetystudyinobesity
AT colaoannamaria vlckdarealtimesafetystudyinobesity
AT muscogiurigiovanna vlckdarealtimesafetystudyinobesity